Heidelberg Pharma GmbH
Schriesheimer Street 101
About Heidelberg Pharma GmbHHeidelberg Pharma offers services for the pre-clinical development of anti-cancer and anti-inflammatory drugs to the pharmaceutical and biotech industry.
CEO and CFO: Jan Schmidt-Brand
CBO: Marcel Linssen
CSO: Andreas Pahl
Please click here for Heidelberg Pharma job opportunities.
36 articles about Heidelberg Pharma GmbH
Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2018
- Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend Their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy
In recent years, checkpoint inhibitors have changed treatment paradigms in cancer.
Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate
Heidelberg Pharma AG today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, exercises its option to further develop a target molecule, and will now continue the development of an Antibody Targeted Amanitin Conjugate based on the target molecule within an exclusive licensing.
Key milestones reached for GMP manufacturing of HDP-101
Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).
Fresh off of striking a research deal with Ladenburg, Germany-based Heidelberg Pharma GmbH, Magenta Therapeutics secured $52 million.The funds will be used to advance Magenta's portfolio of bone marrow transplant medications.
Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma to improve curative bone marrow transplantation.
Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates
Collaboration enables and accelerates Magenta’s research and development efforts across several targeted conditioning programs for bone marrow transplant; Expands application of Heidelberg Pharma ATAC technology to new targets
The companies have agreed to test the combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate superior cancer therapeutics.
Heidelberg Pharma AG Announces Results From Research Collaboration With Heidelberg University and the DKFZ to be Presented at ASH Annual Meeting
The collaboration evaluated the efficacy of the development candidate HDP-101 on multiple myeloma cells isolated from patients. HDP-101 consists of a BCMA antibody, a specific linker and the toxin Amanitin.
The funding measure will consist of a capital increase from authorized capital and from the issue of convertible bonds.
Wilex AG: Subsidiary Heidelberg Pharma Becomes Runner Up In The Category Best New Drug Developer At World ADC Award 2017
Wilex AG: Subsidiary Heidelberg Pharma To Present The Proprietary ATAC Technology Platform At The Annual World ADC Summit
Wilex AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-Target Research Agreement With Takeda For The Development Of Antibody Targeted Amanitin Conjugates
Nordic Nanovector And Heidelberg Pharma Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCs) Targeting Leukaemias